Effect of radioiodine on stimulatory activity of Graves' immunoglobulins.
The effects of 131I therapy on the activity of thyroid stimulating antibody (TSAb) and thyrotrophin binding inhibiting immunoglobulin (TBII) in nineteen patients with Graves' disease have been studied. Prior to 131I administration TSAb was detected in 84%, and TBII in 68% of patients. Following 131I administration TSAb and TBII were detectable in 100% of patients. The elevation 3 months after treatment of the means of both the TSAb and TBII indices for the group of nineteen patients was highly significant compared with pre treatment values. All the patients went into remission during the course of the study and the TSAb index declined in all patients, becoming undetectable in eleven; TBII also declined in most patients but remained detectable in thirteen. The study furthermore afforded the opportunity for a direct comparison of binding with stimulatory activity. These results show that after 131I therapy for Graves' hyperthyroidism there is a transient increase in TSAb as well as TBII, followed by a decline, and that the measurement of binding and stimulatory activities are in good general agreement.
D000906:Antibodies / Q000276:immunology* / Q000378:metabolism; D006111:Graves Disease / Q000188:drug therapy / Q000276:immunology* / Q000378:metabolism; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology* / Q000378:metabolism; D018828:Immunoglobulins, Thyroid-Stimulating; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D013961:Thyroid Gland / Q000276:immunology* / Q000378:metabolism
D000906:Antibodies; D007074:Immunoglobulin G; D018828:Immunoglobulins, Thyroid-Stimulating; D007457:Iodine Radioisotopes